Initial Phase 1 Dose Escalation Data of ORIC-114 in Patients with EGFR and HER2 Exon 20 Mutations Demonstrates Potential Best-In-Class Profile

<p>CNS activity observed at multiple dose levels, including the first reported confirmed CNS complete response by an EGFR exon 20 inhibitor in a patient with documented untreated brain metastases Systemic responses observed at multiple dose levels in heavily pre-treated NSCLC patients, characterized by 81% having received prior EGFR exon 20 targeted agents and 86% having CNS […]</p>
<p>The post <a rel="nofollow" href="https://forextv.com/top-news/initial-phase-1-dose-escalation-data-of-oric-114-in-patients-with-egfr-and-her2-exon-20-mutations-demonstrates-potential-best-in-class-profile/">Initial Phase 1 Dose Escalation Data of ORIC-114 in Patients with EGFR and HER2 Exon 20 Mutations Demonstrates Potential Best-In-Class Profile</a> appeared first on <a rel="nofollow" href="https://forextv.com">ForexTV</a>.</p>